Printer Friendly

ROBERTS PHARMACEUTICAL ACQUIRES THREE CURRENTLY MARKETED PRODUCT LINES FROM G.D. SEARLE

 EATONTOWN, N.J., Dec. 28 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today that it has completed an agreement with G.D. Searle & Company to acquire three marketed US prescription drug product lines. The acquired products are PROBANTHINE(R) AND BANTHINE(R), antispasmodic drugs used to treat a variety of gastrointestinal disorders, and NORETHIN(R), a popular oral contraceptive agent. The purchase price of the acquisition is approximately $35 million consisting of a series of cash payments over time. In addition, Roberts and Searle have entered into a long term supply agreement. Other terms were not disclosed.
 "We are very pleased with the acquisition of these product lines," stated Dr. Robert A. Vukovich, Roberts, CEO and president. "We are developing a new product, SOMAGARD(R), for the treatment of endometriosis, a common gynecologic disorder, and the acquisition of NORETHIN(R) enables us to establish a franchise in the area of women's health," he continued. "Further, PRO-BANTHINE and BANTHINE are important gastrointestinal products which enjoy broad physician popularity and should continue to provide important sales momentum for Roberts in the future," Dr. Vukovich concluded.
 Roberts Pharmaceutical is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts products are currently marketed in seven countries with operating subsidiary companies in the United States, Canada, and the United Kingdom. Roberts has seven drugs in late stage clinical development and currently markets over 80 different products for urological therapy, pain management, cough/cold, gastrointestinal disease, endocrine disorders and dermatological conditions.
 -0- 12/28/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals Corporation, 908-389-1182/
 (RPCX)


CO: Roberts Pharmaceutical Corporation; G.D. Searle & Company ST: New Jersey IN: MTC SU: TNM

LR-OS -- NY006 -- 9993 12/28/92 10:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 28, 1992
Words:301
Previous Article:AMERICAN MEDICAL RESPONSE COMPLETES ACQUISITION; NATION'S LEADING PROVIDER OF AMBULANCE SERVICES COMPLETES ACQUISITION OF DENVER OPERATION
Next Article:ENSERCH DETERMINES TAXABILITY OF 1992 DIVIDENDS
Topics:


Related Articles
ROBERTS PHARMACEUTICAL ACQUIRES THREE CURRENTLY MARKETED PRODUCT LINES FROM G.D. SEARLE
SEARLE ACQUIRES 100 PERCENT OF ITALIAN JOINT VENTURES
ROBERTS PHARMACEUTICAL CORPORATION ACQUIRES FOUR PRESCRIPTION PRODUCTS FROM SEARLE CANADA INC.
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES PRODUCT ACQUISITION AGREEMENT WITH BRISTOL-MYERS SQUIBB
ROBERTS PHARMACEUTICAL CORPORATION TO ACQUIRE NITRODISC ANTI-ANGINAL DRUG FROM G.D. SEARLE
ROBERTS PHARMACEUTICAL CORPORATION COMPLETES ACQUISITION OF U.S. NITRODISC PRODUCT LINE FROM SEARLE
Roberts Pharmaceutical Corporation to Acquire Searle's FDA/HPB Approved Manufacturing Facility From Monsanto Canada Inc.
Watson Pharmaceuticals Enters Into Agreement to Acquire Oral Contraceptive Products From G.D. Searle & Co.
Watson Pharmaceuticals Completes Acquisition of Three Oral Contraceptive Products From G.D. Searle & Co.
Pharmacia Corporation Expands World Headquarters.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters